Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, PCR, Pcr Kits, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits, Uncategorized, Vector & Virus, Western Blot

Association of CRX genotypes and retinal phenotypes confounded by variable expressivity and electronegative electroretinogram.

Association of CRX genotypes and retinal phenotypes confounded by variable expressivity and electronegative electroretinogram.

A framework for understanding the phenotypic features of CRX retinopathy is established.To do phenotype-genotype correlation analysis in two groups of patients with heterozygous mutation in a different location than the CRX gene, encoding the cone rod retrospective homeobox.Multicenter study.Twenty- one of 14 Japanese patients families with heterozygous record mutation.

Retrospective CRX analysis.Clinical data on CRX mutation, symptoms, the best corrected visual acuity (BCVA), visual field, fundus photography, fundus auto-fluorescence, optical coherence tomography, and Electroretinograms (ERGs) .Six CRX heterozygous mutations were identified in different subjects. Twelve patients from 9 families together p.R41W mutation and 1 patient had a mutation p.R43C, which both affect the homeobox domain of CRX.

These patients often featured adult-onset retinal dystrophy macular degeneration. In contrast, 5 patients with mutations downstream (p.S204fs, p.S213fs, p.G243X, and p.L299F) displayed retinal degeneration or macular degeneration with bone-spicule pigmentation. Three asymptomatic carriers with different mutations (p.R41W, p.S213fs, and p.G243X) is present in both groups. Almost all the patients and operators have electronegative ERG in response to the light flash under dark adaptation.

There is no cross-sectional relationship between age and BCVA of patients, despite the progressive reduction BCVA.Heterozygous mutations within or downstream of the homeobox domain in the CRX-related phenotypes related to the difference of the retina, which is confounded by the variable expressivity and electronegative ERGs. CRX mutations should be considered in patients with electronegative ERG with minimal or no changes in the macula. This article is protected by copyright. All rights reserved.

Association of CRX genotypes and retinal phenotypes confounded by variable expressivity and electronegative electroretinogram.
Association of CRX genotypes and retinal phenotypes confounded by variable expressivity and electronegative electroretinogram.

X-linked retinoschisis peripheral without macular involvement: a case series with genetic confirmation RS1.

Background: X-linked Juvenile Retinoschisis (JXLRS) is a hereditary retinopathy usually presents with macular retinoschisis. In this study, we describe a group of patients who presented with peripheral retinoschisis without schisis.Materials and macular Methods: Retrospective case series of three patients with genotype RS1 JXLRS confirmed genetically identified.

Retinoschisis presence macula and / or peripheral assessed by optical coherence tomography (OCT), the width of the field fluorescein angiography, clinical ophthalmoscopy and fundus photography.Results color: The eyes of three patients with retinoschisis peripheral JXLRS not schisis or atrophic macular October ERG is available in one patient and showed no decrease in scotopic b-wave combined response.

Conclusions rod-cone: RS1 mutations can cause the macula-sparing JXLRS phenotype. JXLRS diagnosis should be considered for young males presenting with peripheral retinoschisis even if there is no evidence of schisis macula.


Objective: To describe the phenotype and genotype in young women with Danon disease. Methods: Patients underwent eye examination including best corrected visual acuity (BCVA), fundus photography and fundus autofluorescence (FAF), full-field electroretinography (full-field ERG), multifocal ERG, optical coherence tomography (OCT) and SAP-Humphrey 30- 2 at the age of 20 and 25.

c-Myc Oncoprotein
MBS438133-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myc Oncoprotein
MBS438133-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myc Oncoprotein
MBS438133-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myc Oncoprotein
MBS438133-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS438133-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS438246-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myc Oncoprotein
MBS438246-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myc Oncoprotein
MBS438246-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myc Oncoprotein
MBS438246-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS438246-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-Myb Oncoprotein
MBS438289-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myb Oncoprotein
MBS438289-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myb Oncoprotein
MBS438289-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myb Oncoprotein
MBS438289-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myb Oncoprotein
MBS438289-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381576-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myc Oncoprotein
MBS4381576-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381576-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381576-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381576-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381598-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myc Oncoprotein
MBS4381598-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381598-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381598-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381598-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381109-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

c-Myc Oncoprotein
MBS4381109-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381109-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

c-Myc Oncoprotein
MBS4381109-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

c-Myc Oncoprotein
MBS4381109-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

c-erbB-2 Oncoprotein; Clone SP3
A20100 2 ml
EUR 230.4

c-erbB-2 Oncoprotein; Clone SP3
A00100 6 ml
EUR 414

c-erbB-2 Oncoprotein; Clone SP3
A00100.0025 25 ml
EUR 1320

c-fos Oncoprotein (Fos)
MBS616430-01mg 0.1mg
EUR 700

c-fos Oncoprotein (Fos)
MBS616430-5x01mg 5x0.1mg
EUR 3010

c-fos Oncoprotein (Fos)
MBS612565-005mg 0.05mg
EUR 765

c-fos Oncoprotein (Fos)
MBS612565-5x005mg 5x0.05mg
EUR 3285

Rabbit Anti-C-erbB-2 Oncoprotein
1107NF-225M 5ml
EUR 180

Rabbit anti-c-erbB-2 Oncoprotein
1107NF-V2016 0.5ml
EUR 180

c-fos Oncoprotein (Fos) (AP)
MBS6466283-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (AP)
MBS6466283-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (PE)
MBS6466293-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (PE)
MBS6466293-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (APC)
MBS6466284-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (APC)
MBS6466284-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (HRP)
MBS6466287-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (HRP)
MBS6466287-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (FITC)
MBS6466286-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (FITC)
MBS6466286-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (Biotin)
MBS6466285-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (Biotin)
MBS6466285-5x01mL 5x0.1mL
EUR 4310

HPV16 E7 Oncoprotein ELISA Kit
VPK-5045 96 assays
EUR 888

HPV16 E7 Oncoprotein ELISA Kit
VPK-5045-5 5 x 96 assays
EUR 3580.8

HPV18 E7 Oncoprotein ELISA Kit
VPK-5046 96 assays
EUR 888

HPV18 E7 Oncoprotein ELISA Kit
VPK-5046-5 5 x 96 assays
EUR 3580.8

PTEN (Tumor Suppressor Oncoprotein)
MBS4380472-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

PTEN (Tumor Suppressor Oncoprotein)
MBS4380472-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

PTEN (Tumor Suppressor Oncoprotein)
MBS4380472-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

PTEN (Tumor Suppressor Oncoprotein)
MBS4380472-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

PTEN (Tumor Suppressor Oncoprotein)
MBS4380472-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

Stathmin 1 (Oncoprotein 18, STMN1)
MBS621199-01mg 0.1mg
EUR 490

Stathmin 1 (Oncoprotein 18, STMN1)
MBS621199-5x01mg 5x0.1mg
EUR 2055

Stathmin 1 (Oncoprotein 18, STMN1)
MBS622533-01mg 0.1mg
EUR 490

Stathmin 1 (Oncoprotein 18, STMN1)
MBS622533-5x01mg 5x0.1mg
EUR 2055

Stathmin/Metablastin/Oncoprotein 18
MBS556164-05mL 0.5mL
EUR 455

Stathmin/Metablastin/Oncoprotein 18
MBS556164-5x05mL 5x0.5mL
EUR 1895

Stathmin/Metablastin/Oncoprotein 18
MO47065 0.5 ml
EUR 278.1

Stathmin 1 / Oncoprotein 18 Antibody
abx115844-100g 100 µg Ask for price

Stathmin 1 / Oncoprotein 18 Antibody
abx115844-10g 10 µg
EUR 612.5

Stathmin 1 / Oncoprotein 18 Antibody
20-abx115844
  • Ask for price
  • Ask for price
  • 50 ul
  • 150 ul

Stathmin 1 / Oncoprotein 18 Antibody
abx115844-200g 200 µg Ask for price

ErbB2 (c-erbB2HER2, neu Oncoprotein)
MBS6507450-01mL 0.1mL
EUR 660

ErbB2 (c-erbB2HER2, neu Oncoprotein)
MBS6507450-5x01mL 5x0.1mL
EUR 2810

c-Myc Oncoprotein(MYC2895R), 1mg/mL
BNUM2895-50 1uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

c-Myc Oncoprotein(MYC2895R), 0.2mg/mL
BNUB2895-100 1uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

c-Myc Oncoprotein(MYC2895R), 0.2mg/mL
BNUB2895-500 1uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

c-fos Oncoprotein (Fos) (MaxLight 405)
MBS6466288-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (MaxLight 405)
MBS6466288-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (MaxLight 490)
MBS6466289-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (MaxLight 490)
MBS6466289-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (MaxLight 550)
MBS6466290-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (MaxLight 550)
MBS6466290-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (MaxLight 650)
MBS6466291-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (MaxLight 650)
MBS6466291-5x01mL 5x0.1mL
EUR 4310

c-fos Oncoprotein (Fos) (MaxLight 750)
MBS6466292-01mL 0.1mL
EUR 990

c-fos Oncoprotein (Fos) (MaxLight 750)
MBS6466292-5x01mL 5x0.1mL
EUR 4310

c-erbB-2 Oncoprotein; Clone SP3 (Ready-To-Use)
A00100-0002 2 ml
EUR 114.44

c-erbB-2 Oncoprotein; Clone SP3 (Ready-To-Use)
A00100-0007 7 ml
EUR 236.57

c-erbB-2 Oncoprotein; Clone SP3 (Ready-To-Use)
A00100-0025 25 ml
EUR 843.41

Human HPV 16 E7 Oncoprotein ELISA Kit
DEIASL171 96T
EUR 720
Description: cell lysates, tissue lysates, cervical smears, plasma, serum

p-53 Oncoprotein Antibody, Concentrate
MAB379C 0.2ml
EUR 495

Recombinant Gallid herpesvirus 2 Oncoprotein MEQ (MDV005)
MBS1478027-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1215

Recombinant Gallid herpesvirus 2 Oncoprotein MEQ (MDV005)
MBS1478027-002mgEColi 0.02mg(E-Coli)
EUR 870

Recombinant Gallid herpesvirus 2 Oncoprotein MEQ (MDV005)
MBS1478027-002mgYeast 0.02mg(Yeast)
EUR 1005

Recombinant Gallid herpesvirus 2 Oncoprotein MEQ (MDV005)
MBS1478027-01mgEColi 0.1mg(E-Coli)
EUR 1045

Recombinant Gallid herpesvirus 2 Oncoprotein MEQ (MDV005)
MBS1478027-01mgYeast 0.1mg(Yeast)
EUR 1145

Papillomavirus 16 Oncoprotein Antibody (E7)
GWB-4A7DF0 0.2 mg Ask for price

Papillomavirus 16 Oncoprotein Antibody (E7)
GWB-A82817 0.2 mg Ask for price

Papillomavirus 18 Oncoprotein Antibody (E7)
GWB-A0CFF7 0.2 mg Ask for price

Papillomavirus 18 Oncoprotein Antibody (E7)
GWB-684908 0.2 mg Ask for price

c-Myc Oncoprotein(MYC275 + MYC909), 0.2mg/mL
BNUB1269-100 100uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

c-Myc Oncoprotein(MYC275 + MYC909), 0.2mg/mL
BNUB1269-500 500uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

c-Myc Oncoprotein(MYC275 + MYC909), 1mg/mL
BNUM1269-50 50uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380666-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380666-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380666-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380666-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380666-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380667-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380667-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380667-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380667-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380667-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380668-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380668-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380668-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380668-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

PMEPA1/TMEPAI (Tumor Suppressor Oncoprotein)
MBS4380668-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

ErbB2, p185 (c-erbB2, HER2, neu Oncoprotein)
MBS624467-02mg 0.2mg
EUR 845

ErbB2, p185 (c-erbB2, HER2, neu Oncoprotein)
MBS624467-5x02mg 5x0.2mg
EUR 3660

Oncoprotein-induced transcript 3 protein
AP86295 1mg
EUR 2640

Oncoprotein-induced transcript 3 protein
AP86547 1mg
EUR 2640

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCP1269-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCR1269-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), RPE conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCAP1269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCAP1269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCH1269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCH1269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNCA1269-250 250uL
EUR 459.6
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), APC conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC431269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC431269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC611269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC611269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC551269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC551269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC051269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC051269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC811269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC811269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC801269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC801269-500 500uL
EUR 652.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc Oncoprotein (MYC275 + MYC909) Antibody
BNC701269-100 100uL
EUR 238.8
Description: Primary antibody against c-Myc Oncoprotein ( MYC275 + MYC909), CF770 conjugate, Concentration: 0.1mg/mL

Electrooculography, fluorescein angiography (FA), indocyanine angiography and October angiography is performed only once. Genetic testing using a panel of Next-Generation Sequencing and protein expression LAMP2 immunohistochemical analysis performed in explanted hearts of patients, and cardiology and ophthalmology patient records were retrospectively reviewed.

Dave

Leave A Comment